Evidence map›Paper›PMID 39587121›Full record

ArticleScientific reports2024

The combination of CSF neurofilament light chain and glial fibrillary acidic protein improves the prediction of long-term confirmed disability worsening in multiple sclerosis.

Simon Thebault, Seyed-Mohammad Fereshtehnejad, Hailey P Bergman, Gautier Breville, Mohammad Abdoli, Ronald A Booth, Giulia Fadda, Mark S Freedman, Gauruv Bose

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Exercise Training and Biomarkers of Neuroaxonal Injury in Multiple Sclerosis: Narrative Review.International journal of environmental research and public health · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Simon ThebaultNeurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada. thesdx@gmail.com.
Seyed-Mohammad FereshtehnejadNeurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.
Hailey P BergmanNeurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.
Gautier BrevilleNeurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.
Mohammad AbdoliNeurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.
Ronald A BoothNeurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.
Giulia FaddaNeurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.
Mark S FreedmanNeurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.
Gauruv BoseNeurology, The Ottawa Hospital, 501 Smyth Road, Room 4118, Ottawa, ON, K1H 8L6, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our objective was to evaluate the individual and combined prognostic attributes of baseline serum and CSF measurements of Neurofilament light chain (sNfL, cNfL) and glial fibrillary acidic protein (sGFAP, cGFAP) on long term clinical outcomes in MS. In this retrospective single center study, patients with serum and CSF stored at first MS presentation and > 15-years of follow-up were analyzed. NfL and GFAP were quantified from cryopreserved samples using a digital immunoassay and analyzed as predictors of confirmed disability worsening (CDW). Sixty patients (70% female) underwent baseline tandem CSF and serum sampling and were followed for a mean of 17.8 years (SD 2.5). 32 developed CDW. By logistic regression, while sNfL cNfL and cGFAP showed prognostic merit (AUC 0.72, 0.70, 0.62 respectively), sGFAP did not (AUC 0.5). The combination of cNfL and cGFAP improved CDW prediction compared to either measure considered in isolation (AUC 0.72). The optimal predictive cut-off for CDW (Youden's index) for cNfL was 596 pg/mL and for cGFAP was 8160 pg/mL. Kaplan-Meier analysis of the cutoff-defined 'high-high' and 'low-low' combined cNfL and cGFAP groupings improved prediction of CDW compared to either marker individually (Hazard ratio 4.5 (95% CI 2.7-18.3), Logrank P < 0.0001). Cox Proportional Hazards regression demonstrated that high baseline cNfL and cGFAP were independently prognostic of subsequent CDW after adjusting for baseline age, sex, EDSS score and subsequent treatment exposure. Each unit increase in Ln(cNfL) and Ln(cGFAP) was respectively associated with an additional hazard of 2.36 (95% CI 1.12-5.52) and 2.26 (95% CI 1.03-5.21). CSF NfL and GFAP are independently prognostic of long-term clinical worsening in MS, and may represent a complementary pairing.

Indexed as

BiomarkersGlial Fibrillary Acidic ProteinMultiple SclerosisNeurofilament ProteinsAdultDisease ProgressionFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament Proteins

Identifiers

PMID39587121
PMCPMC11589836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.